|
業務類別
|
Biotechnology |
|
業務概覽
|
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH. |
| 公司地址
| 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065 |
| 電話號碼
| +1 650 327-3270 |
| 傳真號碼
| +1 650 327-3218 |
| 公司網頁
| https://www.corcept.com |
| 員工數量
| 730 |
| Dr. Hazel Hunt, PhD |
Chief Scientific Officer |
-- |
17/04/2026 |
| Dr. William Guyer, Pharm.D. |
Chief Development Officer |
美元 706.39K |
17/04/2026 |
| Mr. Joseph Douglas Lyon |
Chief Accounting Officer and Chief Technology Officer |
-- |
17/04/2026 |
| Mr. Atabak Mokari |
Chief Financial Officer and Treasurer |
美元 566.35K |
17/04/2026 |
| Dr. Joseph K. Belanoff, M.D. |
Director, President and Chief Executive Officer |
美元 1.18M |
17/04/2026 |
| Mr. Sean Maduck |
President, Corcept Endocrinology |
美元 648.86K |
17/04/2026 |
| Mr. G. Charles Robb |
Chief Business Officer and Secretary |
美元 711.41K |
17/04/2026 |
|
|
| Mr. Joshua M. Murray |
Independent Director |
17/04/2026 |
| Mr. David L. Mahoney |
Independent Director |
17/04/2026 |
| Mr. Daniel N. Swisher,Jr |
Independent Director |
17/04/2026 |
| Mr. George Leonard Baker, Jr |
Independent Director |
17/04/2026 |
| Dr. Gregg H. Alton, J.D. |
Independent Director |
17/04/2026 |
| Dr. Joseph K. Belanoff, M.D. |
Director, President and Chief Executive Officer |
17/04/2026 |
| Ms. Kimberly Park |
Independent Director |
17/04/2026 |
| Mr. James N. Wilson |
Chairman of the Board |
17/04/2026 |
|
|
|
|
